CG Oncology, Inc. research snapshot
CGON AI stock analysis currently reads CG Oncology as a late-stage biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer. Positive Phase 2 CORE-008 and pivotal Phase 3 BOND-003 data support a BLA filing planned for Q4 2026, but the stock carries binary approval risk, no commercial revenue, and significant operating cash burn. At the July 12, 2026 data cutoff, CGON traded near $75.24 with a verified market capitalization near $6.64 billion. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$75.24
Market cap
$6.64 billion
AI score
52 / 100
Rating
Late-stage bladder cancer biotech with binary approval catalyst ahead
Trend status
Near 52-week high after positive Phase 2 CORE-008 data; BLA filing expected Q4 2026
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CG Oncology is developing cretostimogene, an oncolytic immunotherapy for bladder cancer, addressing high unmet need in BCG-unresponsive NMIBC where treatment options are limited. | Medium |
| Moat | Moat is unproven at commercial scale. Potential moat comes from oncolytic virus patent protection, first-mover clinical data in NMIBC, manufacturing know-how, and regulatory exclusivity, but CBCR and competitor therapies may narrow the advantage. | Low-medium |
| Management | CEO Dr. Kuan leads a lean 142-person organization. Management has advanced cretostimogene through Phase 3 with strong data, raised capital effectively (IPO and follow-on), and preserved $1.08 billion cash, but has not yet demonstrated commercial execution. | Medium |
| Financial trend | Pre-revenue biotech with R&D spending of roughly $60 million per quarter. TTM revenue of $5.07 million (grant/research income), net loss of $186.74 million, and levered free cash flow of -$105.89 million. Cash runway through at least 2028. | High |
| Valuation | At $75.24, CGON carries a $6.64 billion market cap and $5.57 billion enterprise value. Pre-revenue, so PE and EV/EBITDA are not meaningful. Valuation reflects probability-weighted peak sales estimates for cretostimogene in NMIBC. | Medium |
| Technical trend | CGON has rallied from its $23.65 IPO-year low to near the $75 to $77 52-week high zone. The stock has more than tripled from its lows, showing strong momentum driven by clinical catalysts. Technical analysis is limited by relatively short trading history. | Low-medium |
| Risk level | Main risks are binary FDA approval outcome, clinical trial failure, commercial adoption risk, competitive pressure from Keytruda and other NMIBC therapies, manufacturing challenges, reliance on key personnel, and potential shareholder dilution. | Medium |
| AI confidence | High for descriptive facts and financial data, medium-low for forward approval and valuation scenarios. | Medium data confidence |
| Investment certainty | Low to medium certainty. The page frames scenario ranges and milestone tracking, not a buy or sell instruction. | Low-medium |
CGON AI stock forecast
The CGON AI stock forecast uses scenario ranges around the $75.24 quote and the probability-weighted value of cretostimogene for NMIBC. The framework produced a bearish area near $40 to $50, a base area near $85 to $105, and a bullish area near $120 to $145 depending on approval outcomes, label breadth, and commercial execution.
$120 to $145
More likely if Phase 3 BOND-003 data confirms strong efficacy, BLA filing in Q4 2026 leads to timely FDA approval with a broad label in BCG-unresponsive NMIBC, commercial launch generates rapid adoption, and PIVOT-006 data supports additional label expansion into intermediate-risk NMIBC.
$85 to $105
More likely if cretostimogene receives FDA approval with a manageable label, initial commercial uptake is steady but not explosive, competition from Keytruda and emerging gene therapies limits peak market share, and the company executes its pre-commercial buildout efficiently.
$40 to $50
More likely if BOND-003 results show weaker-than-expected efficacy or unexpected safety signals, FDA issues a Complete Response Letter requiring additional trials, competitor therapies gain NMIBC share, manufacturing scale-up encounters delays, or cash burn requires dilutive financing.
CGON AI technical analysis
CGON AI technical analysis draws on limited public trading history (IPO in January 2024, ~2.5 years) and recent clinical catalyst-driven moves as of the July 12, 2026 data cutoff. The stock has rallied sharply from its 52-week low of $23.65 to near the $75 to $77 resistance zone, with momentum supported by positive Phase 2 CORE-008 and Phase 3 BOND-003 anticipation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $75.24 | Quote snapshots around the July 10, 2026 cutoff placed CGON near $75.24 after a strong 2026 rally. |
| Near support | $65 to $70 | The $65 to $70 zone represents a prior consolidation area during June 2026, serving as the first pullback level to watch. |
| Deeper support | $50 to $55 | Prior to the CORE-008 driven rally in May 2026, CGON traded in the $50 to $55 range, making this a secondary support zone. |
| 52-week low support | $23.65 | The IPO-year low of $23.65 represents an extreme downside reference point if clinical catalysts fail to materialize. |
| Near resistance | $76 to $77 | The 52-week high zone near $76 to $77 is immediate overhead resistance, with the close above $75 pushing toward a new high. |
| Breakout resistance | $90 to $100 | Analyst price targets cluster around $80 to $108, making the $90 to $100 zone a psychological and technical target on a breakout. |
| Volume | Average volume near 1.07 million shares | Google Finance and Yahoo Finance both list average volume near 1.0 to 1.2 million shares, moderate for a mid-cap biotech. |
| Volatility | Approximately 3x above the 52-week low | CGON has tripled from its $23.65 low, reflecting significant clinical catalyst-driven volatility typical of pre-revenue biotech stocks. |
| Invalidation | Close below $50 | A decisive close below $50 would weaken the clinical catalyst-driven uptrend and suggest the market is pricing in a higher probability of regulatory setbacks. |
CGON AI trading strategy
The CGON AI trading strategy is a rules-based research framework for monitoring a pre-revenue biotech stock driven by binary clinical and regulatory catalysts. It is not personal advice and should be paired with clinical trial timelines, FDA communication updates, competitor trial readouts, and a defined position sizing framework.
Track BOND-003 final data, PIVOT-006 interim readout, BLA filing and acceptance, FDA advisory committee calendar, and label negotiation. Position sizing should reflect the binary nature of these events.
A significant portion of valuation depends on FDA approval assumptions. Define maximum exposure per catalyst event. A CRL or safety signal would likely cause a severe valuation reset.
If cretostimogene is approved, watch early prescription trends, urologist adoption, reimbursement coverage decisions, and quarter-over-quarter revenue growth. An approved product with growing sales supports a re-rating toward commercial-stage biotech multiples.
Commercial execution risk is significant for a 142-employee company. Monitor sales force buildout, KOL engagement, and payer coverage breadth. Disappointing launch trajectory would compress the valuation multiple.
Track cash runway (quarterly burn rate), BLA acceptance and FDA review timeline, CORE-008 and PIVOT-006 data readouts, competitor trial results (Keytruda, gene therapies), insider transactions, and analyst revisions.
Reduce exposure if cash runway shortens without a clear non-dilutive financing path, if competitor data threatens cretostimogene positioning, or if insider selling accelerates ahead of a binary event.
Investment research summary
CG Oncology is developing cretostimogene, an oncolytic immunotherapy that uses a modified adenovirus to selectively replicate in cancer cells and stimulate an anti-tumor immune response. Urologists and oncologists need better treatments for BCG-unresponsive NMIBC patients who currently face limited options beyond radical cystectomy.
Cretostimogene is protected by composition-of-matter and method-of-use patents, oncolytic virus manufacturing expertise, and first-mover clinical data in NMIBC gene therapy. The moat is unproven commercially and could narrow if competitors develop more convenient or more effective alternatives.
The thesis fails if BOND-003 data disappoints, FDA requires additional trials, commercialization struggles with a small sales force, Keytruda or other competitors capture NMIBC share, manufacturing scale-up fails, or cash burn forces dilutive financing that destroys shareholder value.
Management has driven cretostimogene from early development through pivotal Phase 3 trials, raised substantial capital ($1.08B cash), and built a lean 142-person organization. Capital allocation should be judged by R&D spending efficiency, partnership strategy, and the ability to execute a successful commercial launch.
CG Oncology operates at the intersection of two long-duration trends: the immuno-oncology revolution and the shift toward gene and cell therapies. Bladder cancer is a large and growing market, and NMIBC patients have high unmet need for bladder-sparing options.
At $6.64 billion market cap and $5.57 billion enterprise value, CGON prices in a significant probability of successful approval and commercial launch. Margin of safety is limited for a pre-revenue biotech because binary regulatory risk and execution uncertainty are high.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CGON price | $75.24 | Google Finance quote snapshot | July 10, 2026 |
| Market capitalization | $6.64 billion, verified as $75.24 x 88.20 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Cash and equivalents | $1.08 billion (mrq) | Yahoo Finance balance sheet | July 12, 2026 |
| Enterprise value | $5.57 billion | Yahoo Finance | July 12, 2026 |
| TTM net income | -$186.74 million | Yahoo Finance income statement | July 12, 2026 |
| TTM EPS | -$2.34 | Google Finance, Yahoo Finance | July 10, 2026 |
| Shares outstanding | 88.20 million | Google Finance | July 10, 2026 |
| Q1 2026 net loss | -$60.20 million | Google Finance income statement | July 10, 2026 |
| Analyst consensus | 13 Buy, 1 Hold, average target $91.55 | Google Finance analyst ratings | July 10, 2026 |
| 52-week high / low | $76.60 / $23.65 | Yahoo Finance | July 10, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell CGON stock. Forecast scenarios are based on available public data, clinical trial information, analyst estimates, and stated assumptions as of the data cutoff date and may be wrong. Pre-revenue biotech investing carries significant risk of total capital loss. Always verify current filings, clinical data, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
